Integrative Physiology |
From the Department of Medicine (K.J.-D., T.J.A., J.R.R., R.E.G., M.E.C.), University of Melbourne, Austin and Repatriation Medical CentreRepatriation Campus, West Heidelberg, and Cell Biology of Diabetes Laboratory (K.M.H., C.A.F., P.J.L.), Baker Medical Research Institute, Melbourne, Victoria, Australia.
Correspondence to Dr Peter J. Little, Head, Cell Biology of Diabetes Laboratory, St. Kilda Road Central, Baker Medical Research Institute, PO Box 6492, Melbourne, Victoria 8008, Australia. E-mail peter.little{at}baker.edu.au
| Abstract |
|---|
|
|
|---|
Key Words: experimental diabetes Na+-H+ exchange vascular smooth muscle vascular hypertrophy cariporide
| Introduction |
|---|
|
|
|---|
Diabetes is associated with both microvascular and macrovascular disease, manifested as altered vascular morphology. VSMCs exposed to elevated glucose13 and aortic smooth muscle cells originating from diabetic rabbits or rats14 15 exhibit increased in vitro growth rates. Previous studies on cultured VSMCs exposed to high glucose demonstrated an increase in the rate of NHE.16 In the light of these results, it is possible that alterations in the NHE system might play a role in the development and/or maintenance of vascular disease in diabetes. However, findings in cultured cells may not necessarily reflect the in vivo situation. Thus, the present study investigated in detail the characteristics of NHE in intact mesenteric arteries from streptozotocin-induced diabetic rats. Specifically, the study tests the hypothesis that hyperglycemia and its in vivo metabolic consequences activate NHE in a vascular bed that we have previously shown to exhibit hypertrophy.17 We have also used the NHE inhibitor cariporide18 to determine whether inhibiting the vascular NHE can prevent or reduce the extent of the vascular hypertrophy occurring in this model of diabetes.
| Materials and Methods |
|---|
|
|
|---|
Generation of Diabetic Rats
Male Sprague-Dawley rats (Biological Research Unit,
Baker Medical Research Institute, Prahran, Victoria, Australia)
were used in this study. Ten-week-old rats weighing 250 to 300 g
were randomized into control (nondiabetic) or diabetic groups. Rats
were made diabetic by a single injection of streptozotocin (45 mg/kg
body weight IV).
Mesenteric Vessel Isolation, Analysis,
Mounting, and Tension Normalization
Mesenteric arterioles were processed and weighed as
previously described.17 For
studies of NHE by measurement of pHi, 6 to 9
animals were used in each group, with 1 or 2 vessel segments from each
rat. All vessels were passed through an identical work program, mounted
in the myograph, and then studied at equivalent tensions. Vessels were
set to an internal circumference at which they were held under tension.
The resting tensioninternal circumference relation was then
determined using a computer program (G.A. McPherson, NORMALIZE, 1985
version).
Determination of NHE Activity
To evaluate NHE activity in mesenteric arterioles,
the pHi, rate of recovery from an induced
acidification, cellular buffer capacity of the mesenteric arterioles,
and the calibration of the fluorescence to pH values were
determined.
Measurement of
pHi
pHi was determined by
monitoring the fluorescence of the pH-sensitive dye BCECF. For these
measurements, the vessel (mounted in myograph) was incubated for 0.5
hours in BCECF-AM (10 µmol/L) in HEPES PSS.
Determination of Recovery Rate After Vessel
Acidification and Buffer Capacity
Intracellular acidification was achieved using the
NH4Cl "prepulse" technique. The
Na+-dependent recovery in the absence of
bicarbonate has previously been characterized in vascular smooth muscle
to be due solely to NHE.19
Actual NHE activity is the true proton extrusion rate and was
calculated as the product of the rates of change in
pHi and tissue buffer capacity (ßi).
Therefore, the intrinsic buffering capacity (ßi) of the tissues was
measured using the method of Roos and
Boron20 as shown in
Figure 1
and calculated using the equation
ßi=
(NH4+)i/
pHi.20
|
Data Analysis
Recorded fluorescence ratio values were converted
into pHi values using the calibration curve
obtained for each experiment. The rate of change of
pHi after an acid load
(
pHi/second) was calculated by using
AcqKnowledge software (Waveform Data Analysis for Windows), version
2.02, by Biopac Systems, Inc. Using this program, rates of change along
the recovery curve could be obtained at specified levels of
pHi. The transport rates at each level of
pHi were analyzed using a Hill plot in which log
(V/Vmax-V)
is plotted against
[H+]i.
Vmax for
this calculation was defined operationally as the maximal transport
rate observed after the readmission of Na+
to acid-loaded tissues. This was the rate observed for the pH interval
of
6.84 to 6.86. For this analysis, data from 6 to 9 experiments
were pooled and 108 to 162 rate constants were calculated for each
experimental group and used to generate the composite Hill plots. The
resultant Hill coefficients (the slopes of these graphs) were compared
for control and diabetic animals. We used our estimates of ßi at pH
6.8 to convert the observed rate of change in
pHi to an estimate of the actual
H+ efflux rate
(
H+ concentration/min).
All values are reported as mean±SE. Data between groups were analyzed using unpaired t test or the least significant difference method as specified. P<0.05 was deemed to be statistically significant.
Competitive Reverse TranscriptasePolymerase
Chain Reaction (RT-PCR) for Estimation of NHE-1 Gene Expression
Quantitative RT-PCR was used to determine an accurate
level of mRNA in the pool of total RNA extracted from mesenteric
arterioles.
The NHE-1 primers used were antisense 5'-TGT GTC TGT TAT AGG ACC GCA GCC-3' and sense 5'-CCA GCT CAT TGC CTT CTA CC-3' (2486 to 2730 [244 bp]). To determine the concentration of mRNA, increasing amounts of a specific NHE-1 competitor (as above but minus 2644 to 2676 [212 bp]) were added to the reaction (5 to 1000 fg), and the concentration of NHE-1 mRNA is equivalent to that concentration of competitor required to give the same intensity of radioactivity incorporation.
Administration of Cariporide and Quantification
of Mesenteric Histomorphology
Sprague-Dawley rats weighing 200 to 250 g were
randomized to receive either streptozotocin (45 mg/kg) or citrate
buffer alone. All rats were given free access to standard rat chow
containing 20% protein (Clark, King and Co). The study protocol used 4
groups of rats, as follows: controls, controls plus cariporide,
diabetes, and diabetes plus cariporide. Rats were administered
cariporide (100 mg/kg per day in 3 divided doses) by gavage, and
control animals received water by the same route of administration. The
study was approved by the Ethics Committee of the Austin and
Repatriation Medical Center. For assessment of mesenteric structure,
the vessels were removed, fixed in 10% formalin, and embedded in
paraffin using standard procedures, and the medial layer of vessels and
corresponding lumen areas were determined as previously
described.21 Quantification
of the area of the extracellular matrix (ECM) within the vessel wall
was performed on trichrome-stained sections (Masson) using a
computer-assisted image analysis
system22 and was related as
a ratio of a proportional area to the total area of media or
adventitia.21 22
Chemicals
BCECF-AM was purchased from Molecular Probes. HEPES
and nigericin were purchased from Sigma Chemical Co. Cariporide
(4-isopropyl-3-methylsulfonyl-benzoylguanidine methane sulfonate, HOE
642) was kindly provided as a gift by Aventis.
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
| Results |
|---|
|
|
|---|
Effect of Experimental Diabetes on NHE
Activity
The parameters necessary to fully characterize the
properties of NHE activity in a preparation are resting or basal
pHi, maximal rate of recovery from a maximally
induced acidosis, and sensitivity of the transporter to intracellular
protons. We systematically assessed each of the properties in the rat
mesenteric arteries.
Measurements of Basal
pHi in Mesenteric Arteries
In mounted vessels prepared by exposure to a work
protocol that normalized the preparations, we evaluated resting
pHi and NHE activity in mesenteric arteries at 1
and 3 weeks after the induction of diabetes. The resting
pHi in control mesenteric arteries measured in
bicarbonate-free HEPES-PSS solution averaged 7.12±0.005. The resting
pHi of vessels from rats with diabetes
established for both 1 and 3 weeks was significantly increased to
7.15±0.003 and 7.14±0.006, respectively
(P<0.05)
(Figure 2
).
|
Measurements of Maximal NHE Activity in
Mesenteric Arteries
NHE activity was assessed from the rate of recovery of
pHi after the reintroduction of extracellular
sodium to a vessel acidified by the ammonium chloride withdrawal
technique conducted in sodium-free solution. An example of a typical
experimental trace is shown in
Figure 1
. There was no significant difference
(P>0.05) in the level of
acidification on NH4Cl washout, which averaged
6.80±0.004 across all experimental groups
(Table 1
). The maximal rate of recovery
(Vmax)
averaged 0.198±0.007 pH units/min in control mesenteric arteries
(Table 1
). The maximal rates of recovery were significantly
increased (P<0.05) after 1 and
3 weeks of diabetes, averaging 0.246±0.006 and 0.238±0.007 pH
units/min, respectively
(Table 1
).
|
The intrinsic buffer capacity (ßi) at pH 6.8 in mesenteric
arteries from control and diabetic rats averaged 24.83±2.34 mmol/L
H+ in controls and 26.75±2.50 mmol/L
H+ and 26.67±1.95 mmol/L
H+ in 1-week and 3-week diabetic vessels,
respectively
(Table 1
). As there was no significant difference among
these estimates of ßi, data from control and diabetic mesenteric
arteries were combined, and the overall mean value for ßi (25.8
mmol/L H+) was used to calculate the
effective H+ efflux rates
(H+
efflux=
pHi/minxßi), which is the best
estimate of NHE activity. The resultant estimates for
H+ efflux rates were 5.11±0.18 mmol/L
H+ per minute in controls and 6.35±0.16 and
6.14±0.18 mmol/L H+ per minute in 1-week
and 3-week diabetic vessels, respectively
(Figure 3
). Proton efflux rates of both 1-week and
3-week diabetic vessels were significantly higher than those of control
vessels.
|
Dependence of
Na+-H+
Activity on pHi in Mesenteric Arteries
To estimate the affinity of the
NHE for intracellular H+, NHE activity
(measured as the rate of recovery of pHi after
acid loading) was calculated at specific levels of
pHi. The relationship between NHE activity and
pHi was determined by obtaining the
"instantaneous" slope of the recovery line at
pHi intervals of 0.05 pH units, from
pHi 6.85 to 7.0, and for 7.05 and 7.10 (18
points in all, for each experiment). The rate of change of
pHi was then plotted as a function of
pHi (Figure 5
) and fitted to a logistic
sigmoidal function
{minimum+[maximum-minimum]/1+exp[-k*(x-x50)]}.
The dependence of NHE activity on intracellular
H+ was steep and sigmoidal. There was no
significant difference in the
Km
values for mesenteric arteries from control or diabetic animals
(Table 1
), nor was there any significant change in the
proton modifier site as indicated by the Hill coefficient
(Table 1
).
|
Determination of the Biochemical Mechanism of
NHE Activation
Studies using cultured VSMCs demonstrated that the
activation of NHE by treatment with high-glucose media for 24 hours was
associated with increased mRNA for
NHE-1.16 Because the levels
of NHE-1 gene expression are generally quite low, we developed a
competitive RT-PCR assay to determine the levels in the rat mesenteric
arterioles. We determined NHE-1 mRNA in vessels from control and
diabetic animals. NHE-1 mRNA per microgram total mRNA averaged
55.8±6.4 fg (n=5) and was increased by 63.6% to 91.3±12.3 fg (n=4)
(P<0.05) at 3 weeks after the
induction of diabetes with streptozotocin
(Figure 4
).
|
Prevention of Mesenteric Hypertrophy by the NHE
Inhibitor Cariporide
We assessed biochemical and physiological parameters as
well as total mesenteric weight at 3 weeks, and these data are
summarized in
Table 2
. Body weight in diabetic animals was reduced, but
cariporide had no significant effect on body weight. Diabetes was
associated with an increase in blood glucose that was not influenced by
cariporide treatment. There was no significant difference in the
systolic blood pressure between control and diabetic animals, and this
also was not influenced by cariporide treatment. Cariporide
significantly (P<0.01)
attenuated the increase in mesenteric weight in diabetic animals
(Figure 5A
). Mesenteric media/lumen ratio was increased in
diabetes and was significantly reduced
(P<0.0001) by treatment with
cariporide to levels approaching those in control rats
(Figure 5B
). Cariporide treatment did not affect these
parameters in control rats.
|
ECM accumulation, as assessed by trichrome staining, was
increased in both the medial and adventitial layers of mesenteric
vessels of diabetic rats
(Figure 5C
). Cariporide treatment was associated with less
ECM accumulation than in the untreated diabetic rats in both vessel
layers, and cariporide treatment did not alter the amount of ECM in
control rats
(Figure 5C
). Representative sections of trichrome-stained
mesenteric arterioles from each of the 4 experimental groups are shown
in
Figure 6
.
|
| Discussion |
|---|
|
|
|---|
In this study, as a prelude to the investigation of NHE activity in the hypertrophying vessels, we confirmed the time course of the development of mesenteric hypertrophy after streptozotocin administration to adult rats. We observed no increase in mesenteric weight by 1 week but a 56% increase at 3 weeks after treatment.
Previous studies investigating NHE activity in diabetes have
used either blood-borne
cells5 or cultured VSMCs
exposed to high glucose.16
We used isolated, intact blood vessels mounted under tension to study
NHE activity after the vessels have been exposed to the full diabetic
milieu. Our data show that manipulation of the metabolic environment in
intact animals can alter NHE activity in blood vessels. The mean
resting pHi of mesenteric arteries from diabetic
rats was significantly higher than for control rats, as was the rate of
recovery from acid loading
(Vmax)
(see
Table 1
). This increase in apparent
Vmax
could not be explained by an alteration in intrinsic cellular
buffering, because this parameter was the same in control and diabetic
vessels, indicating that the increased
Vmax
reflects increased activity or increased abundance of the glycoprotein
transporter. Furthermore, we demonstrated that the expression of NHE-1
mRNA was increased by >60% at 3 weeks after treatment with
streptozotocin.
The maximum acidification achievable in the mesenteric
arteries (see
Table 1
) was considerably less than that in studies of
cultured cells6 19
but was consistent with previous reports from studies in blood
vessels.23 24 25
The level of acidification was sufficient to cause maximum activation
of the pH recovery process (see
Figure 3
, which shows a distinctive sigmoidal shape with a
plateau at maximal recovery). Hence, and importantly, our methodology
ensured that the measurement represents maximal NHE activity for all
groups of vessels studied.
It has previously been shown that hypertrophy observed in vessels from diabetic rats arises from an increase in the medial cross-sectional area.26 The possible mechanisms for this increase of the cross-sectional area (vascular hypertrophy) are VSMC hypertrophy, cellular hyperplasia, and increased ECM. Previously it has been shown that there is no change in the size of the smooth muscle cells when digested from the diabetic mesenteric vessels.26 Previous studies have suggested not only an increase in ECM in diabetic vessels21 but also a change in the type of fibrillar collagens that are accumulating in the medial layer of the mesenteric vessels from diabetic rats. The present study confirms this increase in ECM accumulation in the diabetic vessels and notes that this is observed in both the medial and adventitial layers.
Our data are consistent with a number of in vitro studies, which also show an association between growth and increased NHE activity in diabetes. For example, diabetes is characterized by renal hypertrophy, and concomitant with this growth response is an elevation of NHE activity in the luminal membrane of the proximal tubule.27 Significantly, NHE activity was elevated in the mesenteric arteries of diabetic rats within 1 week of onset of diabetes, before vascular hypertrophy is apparent.17 This implies that this change in NHE activity is not a manifestation of the trophic response in diabetes, but it may be an important pathogenic mechanism in this response.
To discern the underlying basis for the increased transport activity found in the mesenteric arteries of diabetic rats, we examined the kinetic characteristics of NHE. Altered NHE activity in the mesenteric arteries may result from a change in either the apparent Vmax, Km, or in the Hill coefficient, the latter reflecting an alteration in the properties of the proton modifier site. In the present experiments, kinetic analyses of NHE in mesenteric arteries revealed an enhanced maximal velocity (Vmax) of this exchanger with no change either in the apparent affinity (Km) for H+ or in the activation of the H+ modifier site (Hill coefficient). This pattern of NHE activation suggests that diabetes induces increased expression of NHE and is consistent with in vitro studies of diabetic tissues, which found an increase in NHE Vmax but no change in Km.5 28 Accordingly, we were able to confirm activation of NHE-1 synthesis by demonstrating a substantial (>60%) increase in the expression of NHE-1 mRNA in mesenteric vessels of diabetic rats.
The entire circulation in our animals was, of course, exposed to the hyperglycemic stimulus for prolonged periods. The fact that activation of NHE activity was found in mesenteric arteries of diabetic rats may suggest that hyperglycemia alone is sufficient to activate the antiporter in vivo, but this may not mean that the response is direct. Vascular-derived growth factors both activate NHE8 and increase the steady-state levels of NHE-1 mRNA.29 Transforming growth factor-ß1 gene expression is elevated in the mesenteric arteries of diabetic rats within 1 week,30 which also corresponds to the rise in NHE activity found in this study and to the rise in specific activity of PKC and diacylglycerol levels in diabetic tissues.30 Hyperglycemia also activates expression of vascular endothelial growth factor in VSMCs,31 so it is possible that other growth factors may be responsive to the glycemic environment. Rises in both growth factor expression and NHE activity occur before any significant vascular growth and may represent an early response to diabetes, which then leads to vascular remodeling. Our results showing significant elevation in NHE-1 gene expression in the diabetic model are consistent with the results of Rao et al,29 who demonstrated induction by growth factors, and Williams and Howard,16 who demonstrated induction due to high glucose in cultured VSMCs.
As a cell membrane system, the NHE is subject to pharmacological inhibition. Inhibitors interact with the substrate (sodium) binding site on the exchanger to inhibit activity independent of any operating mechanisms of activation. Amiloride derivatives have been shown to inhibit VSMC proliferation under physiological conditions in vitro, and 2 distinct classes of the NHE inhibitors have been shown to inhibit the development of vascular wall thickening in the rat carotid artery injury model. We chose cariporide to investigate the potential role of NHE inhibition in preventing the development of the mesenteric hypertrophy. Hypertrophy was assessed grossly, as the total weight of the mesentery, and the contribution of medial thickening was also quantified. The data confirmed our earlier finding of increased weight and media after streptozotocin administration and clearly showed that inhibition of NHE with cariporide inhibited the development of the vascular hypertrophy. Furthermore, the data indicate that cariporide did not mediate its antitrophic action via effects on metabolic pathways such as glucose or via hemodynamic pathways such as blood pressure, 2 major pathways in the pathogenesis of diabetic vascular disease.17 32
Hyperactivity of the Na+-H+ antiport has been implicated in the pathogenesis of vascular disease in both hypertension and diabetes.5 6 7 Studies in vitro show that high glucose induces both increased VSMC proliferation13 15 and, in the presence of serum, activation of NHE-1.16 The present in vivo study shows that an early and sustained NHE activation is observed in the mesenteric vasculature. We have further shown that administration of the NHE inhibitor during the onset and early phase of the development of hyperglycemia prevents the development of the vascular hypertrophy without influencing glycemic control. These results clearly show that inhibition of NHE is potentially a target for therapeutic intervention in the rapid development of vascular disease in diabetes.
The reduction in vascular hypertrophy observed with cariporide may be due to a reduction in proliferation, cell hypertrophy, or a reduction in ECM accumulation. Although not all mechanisms were extensively explored in this study, as previously reported a major explanation for the increase in vascular weight and wall/lumen ratio in diabetes relates to ECM accumulation. The link between NHE and ECM accumulation has not been previously investigated in detail. Indeed, NHE activity has been closely linked to cell proliferation, a phenomenon that, although present in this model, appears to be transient and primarily occurs in the endothelial and adventitial layers rather than the smooth muscle cell layer. The lack of the effect of cariporide in control rats suggests that blockade of NHE mediates an effect specific for diabetes. It remains to be determined how NHE activation is linked to matrix deposition, and this warrants further exploration. This would allow us to investigate how NHE-1 inhibition may lead to reduced matrix deposition in diabetes.
| Acknowledgments |
|---|
Received July 13, 2000; revision received October 11, 2000; accepted October 13, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Wang, Q. Peng, J. Zhang, and L. Liu Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain Cardiovasc Res, July 21, 2008; (2008) cvn179v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aker, A. K Snabaitis, I. Konietzka, A. van de Sand, K. Bongler, M. Avkiran, G. Heusch, and R. Schulz Inhibition of the Na+/H+ exchanger attenuates the deterioration of ventricular function during pacing-induced heart failure in rabbits Cardiovasc Res, August 1, 2004; 63(2): 273 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. McRobert, M. Gallicchio, G. Jerums, M. E. Cooper, and L. A. Bach The Amino-terminal Domains of the Ezrin, Radixin, and Moesin (ERM) Proteins Bind Advanced Glycation End Products, an Interaction That May Play a Role in the Development of Diabetic Complications J. Biol. Chem., July 3, 2003; 278(28): 25783 - 25789. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I Bak and J. S Ingwall Contribution of Na+/H+ exchange to Na+ overload in the ischemic hypertrophied hyperthyroid rat heart Cardiovasc Res, March 15, 2003; 57(4): 1004 - 1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Cingolani and M. C. Camilion de Hurtado Na+-H+ Exchanger Inhibition: A New Antihypertrophic Tool Circ. Res., April 19, 2002; 90(7): 751 - 753. [Full Text] [PDF] |
||||
![]() |
M. C. Camilion de Hurtado, E. L. Portiansky, N. G. Perez, O. R. Rebolledo, and H. E. Cingolani Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na+/H+ exchanger Cardiovasc Res, March 1, 2002; 53(4): 862 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Khadilkar, P. Iannuzzi, and J. Orlowski Identification of Sites in the Second Exomembrane Loop and Ninth Transmembrane Helix of the Mammalian Na+/H+ Exchanger Important for Drug Recognition and Cation Translocation J. Biol. Chem., November 16, 2001; 276(47): 43792 - 43800. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, X. T. Gan, J. V. Haist, Q. Feng, X. Lu, S. Chakrabarti, and M. Karmazyn Attenuation of Compensatory Right Ventricular Hypertrophy and Heart Failure following Monocrotaline-Induced Pulmonary Vascular Injury by the Na+-H+ Exchange Inhibitor Cariporide J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 469 - 476. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |